Telomir Pharmaceuticals, Inc. TELO
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is an oncology drug developer. Its lead program, Telomir-Zn (previously referred to as Telomir-1), is in Pre-clinical for Advanced or metastatic triple-negative breast cancer (TNBC); also preclinical work in multiple disease areas.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Telomir-Zn | Advanced/metastatic TNBC (IND cleared; no patient dosing reported); other indications in animal/model systems | small molecule | Pre-clinical |
Recent results and decisions
- Oct 5, 2026n/a Telomir Pharmaceuticals completed a $5.6 million private placement of 4,843,300 common shares at $1.16 per share.
The total gross proceeds received by the Company from the Private Placement, before expenses, were approximately $5.6 million.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.